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Identification of epitopes for class I & class II MHC molecules and B-cells2
CANDIDATE SELECTION: Peptides capable of inducing class I & II MHC molecules response, prioritizing those that can induce the response of as much of these molecules as possible, because
more people will be likely to posses the gene that codifies it. Predictions obtained by IEDB and SYFPEITHI will also be given preference from pan-specific methods. Those peptides predicted by
BepiPred with an elevated threshold and being showed as exposed will be selected as B-cell epitopes. Selected peptides will be sent to synthetize.
IN SILICO DESIGN OF A DENGUE VIRUS VACCINE
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FUNCTION TOOL’S NAME INPUT OUTPUT AVAILABLE AT
DENV DATA RETRIEVAL
UniProt None File containing DENV proteins in FASTA format www.uniprot.org
CLUSTALW File containing DENV proteins in FASTA format
5 files containing DENV serotype-specific and common 
proteins in FASTA format
www.ebi.ac.uk
MHC MOLECULES 
PREDICTION
IEDB MHC I binding Proteins‘ file
File containing 8, 9, 10 & 11 aa-long peptides predicted to be 
recognized by MHC I molecules which are codified by 
available human alleles
www.iedb.org
IEDB MHC II binding Proteins‘ file
File containing peptides predicted to be recognized by MHC II 
molecules which are codified by human alleles
www.iedb.org
SYFPEITHI Proteins‘ file
8, 9, 10, 11 & 15 aa-long peptides predicted to be recognized 
by MHC I & MHC II molecules which are codified by available 
human alleles
www.syfpeithi.de
NetMHCPan Proteins‘ file
8, 9, 10 & 11 aa-long peptides predicted to be recognized by 
MHC I & MHC II molecules which are codified by 
representative human alleles
www.cbs.dtu.dk
B-CELL EPITOPES 
PREDICTION
BepiPred Proteins‘ file
Aminoacidic sequence of the input proteins’ showing a 
specific threshold score for each position as well as if the 
residue is buried or exposed and if it is part of a coil or helix
www.cbs.dtu.dk
RESULT’S FILTERING
AGGRESCAN File containing the candidate peptides and file, in 
FASTA format, containing the sequences of the 
proteins from where such peptides were 
retrieved
File containing candidate peptides which are not part of 
transmembrane helixes or aggregation spots
bioinf.uab.es
TMHMM www.cbs.dtu.dk
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4 Results validation
To test the ability of the liposomes cocktail to induce immune response, an assay with mice will be performed to
validate the results (Figure 3).
Figure 3. Results’ validation process. Administration of liposomes cocktail to mice (A). On one side mice blood extraction
(B1), centrifugation to obtain serum (B2), and specific antibody detection by ELISA using the peptides added to the
liposomes (B3). On the other side extraction of mice lymph nodes (C1), T-cell and B-cell culture (C2) and α, β and γ
interferon detection by sandwich ELISA (C3). The protocol for this assay will be presented to an ethics committee and
modification will be effectuated, if needed. Created with BioRender.com.
3 Liposome preparation
Figure 2. Liposome design. Created with
BioRender.com
Five different types of liposomes will be synthetized, one for each set of
predicted peptides. The liposome containing peptides from the conserved
regions between serotypes will not include B-cell peptides. An universal
TCD4+ response inductor, the PADRE peptide [3], will also be included
alongside with the MHC-I and MHC-II peptides inside the liposome, and B-
cell peptides will be
conjugated to the
liposome’s membrane
(Figure 2).
Evaluation of peptide
incorporation to the
liposome’s membrane
will be performed by
confocal microscopy
and evaluation of
peptid encapsulation
will be performed by
protein quantification
after centrifugation.
Expected results
It would be expected for peptide predictions to identify an epitope codified by a large amount of human alleles capable of inducing both MHC-I and MHC-II response. If such epitope isn’t found, it
would be expected that due to the presence of PADRE, a TCD4+ universal inducer, those peptides capable of inducing a MHC-I response alone would be enough. Referring to B-cell predictions, it
would be expected to find serotype-exclusive peptides with the ability to induce humoral response.
Ultimately, it would be expected to obtain a vaccine design that could be able to confer immunity against all DENV serotypes that could be presented to preclinical and clinical trials. Additionally, as
the vaccine should be able to induce both T-dependent and T-independent humoral response, it could be used as a preventive and therapeutic vaccine.
Figure 1. Schematic representation of
the adaptative immune response. The
major histocompatibility complex
(MHC) plays a major role in the
adaptive immune response. Class I
MHC molecules present antigens to
naïve TCD8+ cells and class II MHC to
TCD4+ cells, which can induce T-
dependent B-cell activation. B-cells
are also capable to recognize epitopes
by their own and produce T-
independent humoral response [2]. For
this reason, induction of these
mechanisms is used in vaccine design.
Image from Skwarczynski, M., & Toth,
I. (2016). Peptide-based synthetic
vaccines. Chemical Science, 7(2), 842–
854.
Background information
Dengue is an infectious disease that causes 390 million new cases of infection every year and 25000
deaths. Its infectious agent is the dengue virus (DENV), a flavivirus which codes for 10 proteins (3
structural and 7 non-structural) in an 11 kb RNA genome [1]. DENV has four different serotypes and is
transmitted through Aedes’ species bite. Despite DENV epitopes being widely studied, Dengvaxia® is the
only available vaccine and it isn’t effective enough. There are other vaccines in clinical trials, but none of
them are peptide-based nor try to combinate class I & II MHC and B-cell epitopes information (Figure 1).
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OBJECTIVES: the purpose of this project is the identification of epitopes that could lead to the 
development of a peptide vaccine for DENV.
METHODOLOGY: Predictions for structural and non-structural proteins from the 4 DENV serotypes will be
performed with the objective to identify its ability to bind to class I & II MHC molecules, as well as to B-
cells. Those peptides predicted to be part of aggregation spots or transmembrane helixes will be
dismissed. In the end, the best candidate peptides will be selected, chemically synthetized, conjugated to
liposomes as carrier molecule and its success to induce immune response will be tested.
